Gender bias in clinical trials of biological agents for severe asthma: A systematic review.
Ontology highlight
ABSTRACT: Asthma is one of the most common chronic diseases characterized by sex disparities. Gender bias is a well-documented issue detected in the design of published clinical trials (CTs). International guidelines encourage researchers to analyze clinical data by sex, gender, or both where appropriate. The objective of this work was to evaluate gender bias in the published CTs of biological agents for the treatment of severe asthma. A systematic review of randomized controlled CTs of the biological agents (omalizumab, benralizumab, reslizumab, mepolizumab or dupilumab) for the treatment of severe asthma was conducted. The literature search was performed using PubMed and EMBASE without language restrictions. This study followed the corresponding international recommendations. We identified a total
SUBMITTER: Ciudad-Gutierrez P
PROVIDER: S-EPMC8459995 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA